antibody recruiting molecule-allogeneic NK-cell combination therapy (Kleo Pharmaceuticals/Green Cross LabCell)

N/A

Report date: 2025/01/26 17:59:54

Base Information

Drug Nameantibody recruiting molecule-allogeneic NK-cell combination therapy (Kleo Pharmaceuticals/Green Cross LabCell)
Drug Alias NameARM-allogeneic NK-cell combination therapy (Kleo Pharmaceuticals/Green Cross LabCell)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionCoronavirus spike glycoprotein inhibitorsImmunoglobulin G modulators
TargetsCoronavirus spike glycoproteinImmunoglobulin G
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGC Cell Corp
China Registration ClassN/A

Develop Information

Active CompaniesGC Cell CorpKleo Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A